My watch list
my.bionity.com  
Login  

Evotec and APEIRON achieve first milestone in immuno-oncology alliance with Sanofi

09-Jan-2018

Evotec AG and APEIRON Biologics AG announced that the companies received the first milestone payment from Sanofi under a 3-party alliance signed in August 2015. The milestone payment of EUR 3 m will be split equally between the two biotech companies. The success payment was triggered when the partners successfully advanced an undisclosed, novel immuno-oncology small molecule into late-stage pre-clinical development. Under the alliance, the three companies work together to identify small molecule leads and targets for next-generation therapies in immuno-oncology, which may complement the pre-clinical and clinical profiles of leading checkpoint inhibitors.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "The Evotec and APEIRON teams are proud to have achieved our first milestone with Sanofi to discover and develop novel immuno-oncology small molecules therapies. It is a first-in-class approach with tremendous potential in combination with marketed checkpoint inhibitors but also as standalone therapy. The field of immuno-oncology will continue to evolve and at Evotec we will continue to invest in this area."

Dr Hans Loibner, Chief Executive Officer of APEIRON Biologics, said: "We are delighted by the progress made in our collaboration with Evotec and Sanofi. Based on our scientific findings and the mode of action, we jointly agreed to accelerate the research and pre-clinical development of this very promising molecule. The successful achievement of this milestone further demonstrates our abilities to drive innovation in the field of immuno-oncology."

Facts, background information, dossiers
  • Evotec
  • Apeiron Biologics
  • milestone payments
  • immuno-oncology
More about Evotec
  • News

    Evotec and Celgene enter into strategic oncology partnership

    Evotec AG announced that Evotec and Celgene Corporation have entered into a long-term strategic drug discovery and development partnership to identify new therapeutics in oncology. Evotec has built one of the industry's broadest and most innovative pre-clinical discovery and development pla ... more

    Evotec expands CRISPR-based technology offering with licence from ERS Genomics

    Evotec AG announced that it has expanded its CRISPR service offering with the addition of a licence from ERS Genomics Limited. With this licence, Evotec gains access to the leading technology for gene editing, thereby complementing and expanding its existing service offering in the CRISPR g ... more

    Evotec and Bayer advance third endometriosis programme into Phase I clinical development

    Evotec AG announced that its multi-target alliance with Bayer has advanced another promising small molecule into Phase I for the treatment of endometriosis, a painful, debilitating reproductive condition that affects approximately 176 million women worldwide. This milestone was achieved und ... more

  • Companies

    Evotec Neurosciences GmbH

    Evotec is a leader in the discovery and development of novel small molecule drugs. The Company has established a powerful platform that is applicable to targets across all therapeutic areas and has specific expertise in the area of Central Nervous System (CNS) related diseases where it is b ... more

    Evotec AG

    Evotec is a leading drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches. The Company operates worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target ... more

More about Apeiron Biologics
More about Sanofi-Aventis
  • News

    Sanofi will get new Head of Global R&D

    Elias Zerhouni, M.D., Head of Global Research and Development will retire from Sanofi on June 30th, 2018, after more than 9 years of distinguished service with the company. He will be succeeded in the post by John C. Reed, M.D. Ph.D. who has been appointed Head of Global Research & Developm ... more

    Sanofi sells European generics business

    Advent International and Sanofi have entered into exclusive negotiations under which Advent would acquire Zentiva, Sanofi's European generics business for €1,9 billion. Advent's offer is firm, binding and fully financed. Advent is a global investor, with over 25 years' experience of investi ... more

    Sanofi to invest €350 million in Canadian vaccine facility

    Sanofi is investing €350 million (CAD $500 million) for the construction of a new state-of-the-art vaccine manufacturing facility at the Sanofi Pasteur Canadian headquarters in Toronto, Ontario. The investment bolsters the company’s Canadian operations and its commitment to advancing public ... more

  • Companies

    Sanofi-Aventis Deutschland GmbH

    Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more

    Sanofi-Aventis Deutschland GmbH

    Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Sanofi-aventis is listed in Paris and in New York. Sanofi Pasteur, the vaccines division of sanofi-aventis Group, provided more than a billi ... more

    sanofi-aventis Groupe

    One of the world's leading pharmaceutical companies and number 1 in Europe. Sanofi-aventis' pharmaceuticals business focuses on six therapeutic areas: diabetes, oncology, thrombosis, cardiovascular diseases, central nervous system (CNS) and internal medicine. About 100,000 employees worl ... more

Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE